When does Banzel (rufinamide) patent/exclusivity expire?
“Banzel” (rufinamide) is subject to U.S. patent and regulatory exclusivity timelines that depend on the specific formulation and each listed patent’s life. DrugPatentWatch tracks those dates and lists the relevant filings and expiry calculations for rufinamide/Banzel.[1]
For the most accurate expiry date(s), check DrugPatentWatch’s page for Banzel/rufinamide and use the “patent expiry” and “exclusivity” dates shown there, since different patents can expire at different times.[1]
Why are there multiple “expiry dates” for Banzel?
Even when a drug name is the same, different legal protections can end on different dates, such as:
- Individual U.S. patents covering the drug substance or specific claims (each has its own expiry)
- Regulatory exclusivities (for example, exclusivity tied to first approval or other qualifying events)
So “the expiry date” often means multiple dates across different protections rather than one single day.
How can you find the exact expiry date for your use case (US vs. other countries)?
If you are checking “expiry” for generic or market-entry timing, you need the jurisdiction (U.S., EU, etc.) and the exact product reference.
DrugPatentWatch is built to help with this by tying dates to specific patents and showing the relevant listings for the drug.[1]
Are generics allowed right after patent expiry?
Not automatically. Even after some patents expire, another remaining patent or exclusivity can still block market entry, and generic manufacturers may need to navigate “patent-after-grant” issues (for example, later-expiring patents asserted against the generic). The remaining patent stack and any active litigation are what ultimately governs entry timing.
DrugPatentWatch’s patent list is the starting point for identifying whether any other protections remain.[1]
---
Sources:
[1] https://www.drugpatentwatch.com/patent/banzel-rufinamide